Facebook
Twitter
Telegram
Report an ErrorEagle Pharmaceuticals Financial Statements 2011-2024 | EGRX
Annual Financial Statements Eagle Pharmaceuticals
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
340 M | 600 M | 629 M | 754 M | 616 M | 891 M | 1.03 B | 1.1 B | 127 M | - | - | - |
Shares |
12.9 M | 13.1 M | 13.5 M | 13.8 M | 14.8 M | 15.1 M | 15.5 M | 15.3 M | 9.96 M | - | - | - |
Historical Prices |
26.3 | 45.9 | 46.7 | 53.8 | 42.3 | 59.8 | 69.2 | 71.9 | 19.4 | - | - | - |
Net Income |
35.6 M | -8.63 M | 12 M | 14.3 M | 31.9 M | 51.9 M | 81.5 M | 2.57 M | -18 M | -6.05 M | -19.4 M | - |
Revenue |
317 M | 172 M | 188 M | 196 M | 213 M | 237 M | 189 M | 66.2 M | 19.1 M | 13.7 M | 2.54 M | - |
Cost of Revenue |
85.5 M | 31.5 M | 33.6 M | 47.9 M | 42.4 M | 33.7 M | 35.8 M | 15.6 M | 11.7 M | 7.38 M | 3.17 M | - |
Gross Profit |
- | - | - | 135 M | 151 M | 180 M | 134 M | 50.6 M | 7.38 M | 6.3 M | -627 K | - |
Operating Income |
81 M | 2.77 M | 33 M | 21.8 M | 36.6 M | 74 M | 53.4 M | 2.56 M | -18.8 M | -8.46 M | -19.8 M | - |
Interest Expense |
4.04 M | 1.64 M | 2.58 M | 2.69 M | 2.74 M | 1.14 M | 8 K | 11 K | 8 K | 309 K | 91 K | - |
EBITDA |
81.6 M | 3.53 M | 33.8 M | 26.5 M | 50.1 M | 79.2 M | 53.2 M | 2.67 M | -18.7 M | -8.32 M | -19.6 M | - |
Operating Expenses |
- | - | - | 113 M | 105 M | 104 M | 82.6 M | 48 M | 26.1 M | 14.8 M | 19.2 M | - |
General and Administrative Expenses |
107 M | 75.3 M | 78.6 M | - | - | 73.1 M | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Income Statement Eagle Pharmaceuticals
| 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
13.1 M | 13.1 M | - | 13.2 M | 12.8 M | 12.7 M | - | 13.1 M | 13.1 M | 13.1 M | - | 13.5 M | 13.7 M | 13.7 M | - | 13.7 M | 13.8 M | 13.9 M | - | 15 M | 14.9 M | 14.8 M | 14.8 M | 15 M | 15.2 M | 15.3 M | - | 15.6 M | 15.6 M | 15.6 M | 15.6 M | 15.6 M | 15.5 M | 14.2 M | 14 M | 14 M | 14 M | 8.86 M | 3.05 M | 3.02 M | 3.05 M | 3.05 M | - | - | - | - | - | - | - | - |
Net Income |
5.16 M | 5.75 M | - | -7.13 M | -9.45 M | 44.1 M | - | -5.62 M | 3.61 M | -421 K | - | 7.06 M | -256 K | -2.87 M | - | -2.39 M | 6.72 M | 8.97 M | - | 14 M | 2.66 M | 2.62 M | - | 15.4 M | 4.5 M | 22.9 M | - | 12 M | 13.1 M | -896 K | 1.22 M | -10.2 M | -8.18 M | 19.7 M | -5.51 M | -9.1 M | -2.93 M | -2.68 M | -3.26 M | -6.53 M | 755 K | -4.8 M | - | - | - | - | - | - | - | - |
Revenue |
64.6 M | 66.3 M | - | 65.9 M | 74.1 M | 116 M | - | 39.9 M | 48.1 M | 41.2 M | - | 49.9 M | 41.9 M | 46 M | 48.3 M | 41.1 M | 56.7 M | 49.8 M | 56.1 M | 51.3 M | 59.3 M | 46.6 M | 46.8 M | 63 M | 50.1 M | 76.8 M | 81.1 M | 37.8 M | 40.9 M | 29.6 M | 18.2 M | 5.74 M | 6 M | 36.3 M | 5.6 M | 2.81 M | 5.79 M | 5 M | 5.49 M | 9.04 M | 5.08 M | 2.48 M | - | - | - | - | - | - | - | - |
Cost of Revenue |
16.9 M | 17.3 M | - | 20.9 M | 21.2 M | 25.2 M | - | 5.49 M | 7.91 M | 8.44 M | - | 8.73 M | 10.3 M | 4.76 M | - | 12.1 M | 18.2 M | 9.55 M | - | 8.62 M | 14.1 M | 7.22 M | - | 4.82 M | 8.91 M | - | - | 10.4 M | 11.5 M | 14.6 M | - | 3.75 M | 3.35 M | 5.95 M | 1.78 M | 2.18 M | 1.56 M | 3.36 M | 2.67 M | 4.45 M | 2.93 M | 1.31 M | - | - | - | - | - | - | - | - |
Gross Profit |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | 36.7 M | 26.2 M | 35.4 M | 36.7 M | 37.5 M | 38.3 M | 40.7 M | 34.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
10.3 M | 11.8 M | - | 9.46 M | 2.2 M | 59.8 M | - | -10.2 M | 10.8 M | -3.77 M | - | 15.4 M | 3.71 M | 4.04 M | 2.9 M | -2.48 M | 9.23 M | 12.2 M | 15.7 M | 18.4 M | 183 K | 2.3 M | 10.4 M | 25 M | 5.9 M | 32.7 M | 28.3 M | 12.3 M | 13.7 M | -897 K | 1.19 M | -10.4 M | -8.34 M | 20.1 M | -6.56 M | -9.11 M | -2.98 M | -3.6 M | -3.06 M | -5.92 M | 1.26 M | -4.31 M | - | - | - | - | - | - | - | - |
Interest Expense |
1.45 M | 1.52 M | - | 1.15 M | 552 K | 366 K | - | 396 K | 422 K | 422 K | - | 489 K | 786 K | 889 K | - | 628 K | 665 K | 686 K | - | 743 K | 701 K | 675 K | - | 527 K | 40 K | 27 K | - | 3 K | 3 K | - | - | 5 K | 3 K | 1 K | 1 K | 2 K | 5 K | 1 K | - | 309 K | 16 K | 145 K | - | - | - | - | - | - | - | - |
EBITDA |
10.4 M | 11.9 M | - | 9.66 M | 2.4 M | 60 M | - | -9.98 M | 11 M | -3.57 M | - | 15.6 M | 3.92 M | 4.29 M | 2.9 M | -2.24 M | 9.47 M | 12.4 M | 15.7 M | 19.3 M | 866 K | 2.65 M | 10.4 M | 25.6 M | 6.33 M | 32.9 M | 28.3 M | 12.8 M | 14 M | -757 K | 1.19 M | -10.4 M | -8.31 M | 20.1 M | -6.55 M | -9.03 M | -2.93 M | -3.57 M | -3.03 M | -5.82 M | 1.34 M | -4.31 M | - | - | - | - | - | - | - | - |
Operating Expenses |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 43.6 M | 47.5 M | 37.6 M | - | 32.9 M | 59.1 M | 44.3 M | - | 38.1 M | 44.2 M | 44.1 M | - | 25.5 M | 27.3 M | 30.5 M | - | 16.1 M | 14.3 M | 16.2 M | 12.2 M | 11.9 M | 8.77 M | 8.61 M | 8.56 M | 15 M | 3.82 M | 6.79 M | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
27.7 M | 28 M | - | 23.5 M | 36.8 M | 22.2 M | - | 18.5 M | 16.6 M | 19.9 M | - | 17.7 M | 18 M | 24.8 M | - | 18.5 M | 17.2 M | 18.1 M | - | 13.9 M | 16 M | 15.2 M | - | 16.7 M | 23.3 M | 18.6 M | - | 11.7 M | 12 M | 12.1 M | - | 5.46 M | 5.11 M | 3.99 M | 3.69 M | 3.85 M | 2.67 M | 1.45 M | 1.34 M | 6.13 M | 1.25 M | 2.95 M | - | - | - | - | - | - | - | - |
All numbers in USD currency